SP-303 for Diarrhea Reduction in AIDS Patients

This study focuses on a treatment called SP-303 for individuals living with AIDS who experience diarrhea. The main goal is to understand if SP-303 can effectively reduce diarrhea symptoms, specifically by decreasing stool weight. The research also aims to evaluate the safety of SP-303 and how long its effects last. This study is important as it could potentially offer a new treatment option for AIDS patients dealing with diarrhea, thereby improving their quality of life. In this study, participants receive SP-303 orally over a period of 6 days. The study is designed as 'double-blind', meaning neither the participants nor the researchers know who is receiving the actual drug or a placebo, a pill without any active ingredients. This helps ensure the results are unbiased. The effectiveness of SP-303 is measured by monitoring changes in stool weight. Safety is evaluated by tracking any side effects or health changes throughout the study period.